PBAC's latest decision on Tocilizumab: Noted (2025). Considered for Tocilizumab biosimilar requested for listing under the same circumstances as the reference brand Actemra for the treatment of active giant cell arteritis, systemic juvenile idiopathic arthritis, and severe active rheumatoid arthritis in both adult and paediatric populations.
PBAC outcome
Noted
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
12
first 2009
Submissions
12
2009 → 2025
Eligible population
Adults and children with active giant cell arteritis, systemic juvenile idiopathic arthritis (≥30 kg and <30 kg populations), and severe active rheumatoid arthritis, with treatment phases defined by initial therapy, continuing therapy, and paediatric-specific criteria (age <18 years).
Therapy area
Rheumatology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Actemra (reference tocilizumab biologic)
Economic model
Cost-minimisation
ICER note
Cost-minimisation basis submission; no ICER calculated as this is a biosimilar listing under the same conditions as the reference brand.
Submission history
Jul 2009: Recommended with restriction · Authority Required
Mar 2010: Recommended with restriction
Nov 2011: Recommended with restriction · Authority Required
Jul 2013: Not recommended · Restricted
Nov 2013: Recommended with restriction · Authority Required
Mar 2016: Recommended with restriction · Authority Required
Jul 2018: Recommended with restriction · Authority Required
Nov 2018: Recommended with restriction · Authority Required
Mar 2019: Recommended with restriction · Authority Required
Mar 2019: Recommended with restriction · Authority Required
Mar 2020: Recommended with restriction · Authority Required